BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CERN//INDICO//EN
BEGIN:VEVENT
SUMMARY:Radioactive arsenic (III) compounds as potential theranostic radio
 pharmaceuticals
DTSTART;VALUE=DATE-TIME:20211011T093000Z
DTEND;VALUE=DATE-TIME:20211011T095000Z
DTSTAMP;VALUE=DATE-TIME:20260904T163645Z
UID:indico-contribution-247@indico.koza.if.uj.edu.pl
DESCRIPTION:Speakers: Monika Łyczko (Institute of Nuclear Chemistry and T
 echnology)\nArsenic compounds have been known and used in medicine for cen
 turies. Arsenic (III) in the form of simple inorganic compounds easily oxi
 dizes\, which makes its administration in the human body difficult. As2O3 
 is now used in the successful treatment of acute promyelocytic leukemia. \
 nThe high affinity of arsenic to sulfur atoms and creating strong bonds wi
 th sulfur-containing compounds provides a wide range of applications of ar
 senic compounds in medicine.\nThe application of arsenic compounds enables
  the use of a wide range of radioactive arsenic isotopes in nuclear medici
 ne\, both in diagnostics and therapy. Arsenic has four isotopes - β+ emit
 ters (70/71/72/74As) and three β- emitters (74/76/77As)\, which can be ob
 tained in a reactor or in an accelerator. The half-lives of As radioisotop
 es are in the range from 53 minutes to 18 days. 72As can be also obtained 
 from the 72Se/72As generator [1\,2]\, which would facilitate the synthesis
  of radiopharmaceuticals in the hospital. Arsenic is also an interesting c
 andidate for use in the innovative β + γ diagnostic technique\, which al
 lows increasing the precision of the examination with the use of a lower d
 ose of the radioisotope for the patient [3].\nFor the synthesis of arsenic
  complexes on a weight scale the ligands containing thiol groups were used
 . The synthesis was carried out in a nitrogen atmosphere under reflux\, an
 d chloroform was used as a solvent. The four arsenic (III) compounds with 
 dithiol ligands were obtained. The compounds were examined by X-ray diffra
 ction and their mass was determined by ESI Q-TOF-MS. The results of both s
 tudies confirmed the expected structure of the tested compounds\, which al
 lowed to determine the retention time of the peaks on HPLC chromatograms. 
 Also\, the UV-Vis spectra of the tested complexes were measured. Toxicity 
 studies of arsenic compounds on NB4 acute promyelocytic leukemia cells wer
 e performed using the MTS test. All compounds as well as As2O3 induced cyt
 otoxicity in a time and dose-dependent manner. \nThe established synthesis
  conditions on a weight scale allowed for the syntheses with the use of th
 e radioactive 76As isotope\, which were examined by TLC and HPLC methods. 
 Radioactive complexes were formed with high efficiency within 0.5 h of syn
 thesis and were relatively stable in human serum.\n\nFunding: This work wa
 s supported by the IAEA Research Contract No: 23299 \n\n[1] E. Chajduk\, K
 . Doner\, H. Polkowska-Motrenko\, A. Bilewicz\, “Novel radiochemical sep
 aration of arsenic from selenium for 72Se/72As generator”\, Appl. Rad. I
 sot.\, vol. 70 pp. 819–822\, 2012.\n[2] M. Jennewein\, A. Schmidt\, A. F
 . Novgorodov\, S. M. Qaim\, F. Rösch\, “A no-carrier-added 72Se/72As ra
 dionuclide generator based on distillation”. Radiochim. Acta\, vol. 92\,
  pp. 245-249\, 2004.\n[3] M. Sitarz\, J.P. Cussonneau\, T. Matulewicz\, F.
  Haddad. “Radionuclide candidates for β+γ coincidence PET: An overview
 ”. Appl Radiat Isot. vol.155\, 108898\, 2020.\n\nhttps://indico.koza.if.
 uj.edu.pl/event/4/contributions/247/
LOCATION:Theranostics Center / on-line
URL:https://indico.koza.if.uj.edu.pl/event/4/contributions/247/
END:VEVENT
END:VCALENDAR